CJC-1295
Also called CJC-1295 (free base), CJC-1295 acetate, CJC-1295 with drug affinity complex (DAC), CJC-1295 DAC acetate
Research and education only. Not medical advice. Talk to a doctor.
In 30 seconds
A long-acting, lab-made version of GHRH, built to stick to albumin in the blood.[2][3]
Small studies in healthy adults found one injection raised growth hormone for 6 days or more.[1]
Not FDA-approved and banned in tested sport. FDA has linked it to serious side effects.[4][7]
How far has the research gotten?
Research over time
Papers on PubMed each year that mention CJC-1295.1 papers in 2025FDA notes that different forms, with and without "DAC", are sold as CJC-1295.[6]
What studies used
What each paper reports. A record of published research, not a recommendation.Two randomized, placebo-controlled, double-blind ascending-dose trials (28 and 49 days) of pharmacokinetics, GH and IGF-I responses, and safety.
The Journal of clinical endocrinology and metabolism · 2006 · PubMed 16352683What the paper reports
Subcutaneous; four ascending single doses (study 1) and two or three weekly or biweekly doses (study 2). The abstract names 30 or 60 microg/kg as the best-tolerated doses. Full dose list not stated in abstract.
Who: Human (healthy adults aged 21-61)Overnight GH pulse patterns (20-minute sampling over 12 hours) before and 1 week after injection, and which GH secretion measures related to the rise in IGF-I.
The Journal of clinical endocrinology and metabolism · 2006 · PubMed 17018654What the paper reports
Single injection of 60 or 90 microg/kg
Who: Human (healthy men aged 20-40)Effects of different dosing intervals on body weight, length, bone length, body composition and pituitary GH mRNA in GHRH-deficient mice.
American journal of physiology. Endocrinology and metabolism · 2006 · PubMed 16822960What the paper reports
2 microg every 24, 48 or 72 h for 5 weeks, starting at 1 week of age
Who: Mouse (GHRH knockout)FDA's list of bulk substances it says may raise significant safety risks if pharmacies compound them. CJC-1295 was on it until its nomination was withdrawn.[4]
What it is, in full 4
CJC-1295 is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), designed to attach to albumin in the blood after injection so that it lasts much longer than natural GHRH.[2][3]
In two placebo-controlled studies in healthy adults, a single under-the-skin injection raised average growth hormone levels for 6 days or more and IGF-I levels for 9 to 11 days, and the estimated half-life was 5.8 to 8.1 days.[1]
In mice lacking their own GHRH, daily injections kept growth and body composition normal, while dosing every 48 or 72 hours was less effective.[3]
FDA says it has identified serious adverse events linked to CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes that several different forms are sold under the same name.[4][6]
Regulatory details 4
Searches of Drugs@FDA (openFDA, active ingredient 'CJC-1295') and DailyMed returned no matches on 2026-10-06. No FDA page opened in this session states its approval status in words.[8]
Checked 2026-10-06FDA's category 2 page lists CJC-1295 in its table of substances previously in category 2 whose nominations were withdrawn. FDA's stated concerns: possible immunogenicity, peptide impurity and characterization issues, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data. Page content current as of 04/22/2026.[4]
Checked 2026-10-06FDA evaluated five CJC-1295-related substances on its own initiative after the nomination was withdrawn and proposed that none be added to the 503A Bulks List. At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, the votes on adding each were: free base 0 yes/13 no, acetate 1 yes/12 no, DAC free base 0/13, DAC acetate 0/13, DAC trifluoroacetate 0/13.[5]
Checked 2026-10-06The 2026 Prohibited List names CJC-1295 (and CJC-1293) as examples of GHRH analogues under S2.2.4 Growth hormone releasing factors. S2 substances are prohibited in and out of competition and are non-Specified.[7]
Checked 2026-10-06Human trials on ClinicalTrials.gov
An intervention search of ClinicalTrials.gov for 'CJC-1295' on 2026-10-06 returned 1 record: NCT00267527, a ConjuChem phase 2 placebo-controlled study of CJC 1295 for 12 weeks in people with HIV-associated visceral obesity, listed as terminated (no reason given in the record).[9]
All sources 10
- Teichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)PubMed / NCBI
- Ionescu M, Frohman LA. J Clin Endocrinol Metab 2006 (PMID 17018654)PubMed / NCBI
- Alba M et al. Am J Physiol Endocrinol Metab 2006 (PMID 16822960)PubMed / NCBI
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 page)U.S. Food and Drug Administration
- Final Summary Minutes, Pharmacy Compounding Advisory Committee, December 4, 2024U.S. Food and Drug Administration
- July 23, 2026 Pharmacy Compounding Advisory Committee - FDA Presentations (introductory remarks on common-name challenges, citing CJC-1295)U.S. Food and Drug Administration
- WADA Prohibited List 2026World Anti-Doping Agency
- openFDA Drugs@FDA search: CJC-1295 (no matches)U.S. Food and Drug Administration (openFDA)
- ClinicalTrials.gov API intervention search: CJC-1295ClinicalTrials.gov / NLM
- DailyMed SPL search: CJC-1295 (0 results)DailyMed / NLM
Tap any purple number to open the source it came from.
Written from the sources above and checked on the date shown. Sources can be incomplete or out of date, and summaries can contain mistakes: read the source. See the terms.